Inside Innovation

At a recent Life Science Washington event in Spokane, local health and research leaders warned that proposed NIH funding cuts could jeopardize medical research, jobs,

Bristol Myers Squibb (BMS), through its subsidiary RayzeBio, has entered a $1.35 billion licensing agreement with Swiss biotech firm Philochem centered around OncoACP3, a radiopharmaceutical

Seattle-based Perspective Therapeutics came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, signaling growing momentum in targeted radiopharmaceuticals. One of the company’s

Two Spokane-based innovation clusters have each secured $140,000 through the Washington State Department of Commerce’s Innovation Cluster Accelerator Program. The Evergreen Bioscience Innovation Cluster will

Bristol Myers Squibb has entered into a partnership with BioNTech, committing up to $11.1 billion to co-develop and commercialize BNT327, a bispecific antibody targeting solid

A combination drug treatment that includes Pfizer’s Braftovi has doubled survival time for some patients with advanced colorectal cancer, according to recently released late-stage trial

With support and partnership from Alexandria Real Estate Equities, Fred Hutch unveiled a state-of-the-art learning lab where high school and college students can learn and

The Allen Institute has opened a new 1,327 square-foot Education Lab, providing immersive, authentic learning experiences for learners at all levels. “Our unique lab experiences

A consortium of researchers, including those from Seattle’s Allen Institute for Brain Science and the University of Washington, created a new molecular toolkit with potential

Seattle’s Allen Institute launched a bold new initiative, CellScapes, which uses AI and mathematics to create a novel framework for understanding cellular biology. With 75

Bothell-based VerAvanti announced it has raised $31.5 million to further develop its ultra-thin imaging scopes aimed at preventing strokes and heart attacks. Founded on technology

Kirkland-based Prevencio has earned FDA breakthrough device designation for its HART CADhs test, an AI-powered, multi-protein blood test for detecting obstructive coronary artery disease. HART